ProQR Therapeutics PRQR Stock
ProQR Therapeutics Price Chart
ProQR Therapeutics PRQR Financial and Trading Overview
| ProQR Therapeutics stock price | 2.09 USD |
| Previous Close | 1.75 USD |
| Open | 1.73 USD |
| Bid | 0 USD x 3000 |
| Ask | 0 USD x 1400 |
| Day's Range | 1.69 - 1.76 USD |
| 52 Week Range | 0.68 - 3.85 USD |
| Volume | 272.3K USD |
| Avg. Volume | 785.36K USD |
| Market Cap | 137.59M USD |
| Beta (5Y Monthly) | 0.022535 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.48 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.98 USD |
PRQR Valuation Measures
| Enterprise Value | 19.72M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.4 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 32.237743 |
| Price/Book (mrq) | 2.3319616 |
| Enterprise Value/Revenue | 4.62 |
| Enterprise Value/EBITDA | -0.35 |
Trading Information
ProQR Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.022535 |
| 52-Week Change | 131.92% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3.85 USD |
| 52 Week Low | 0.68 USD |
| 50-Day Moving Average | 2 USD |
| 200-Day Moving Average | 1.97 USD |
PRQR Share Statistics
| Avg. Volume (3 month) | 785.36K USD |
| Avg. Daily Volume (10-Days) | 428.9K USD |
| Shares Outstanding | 80.94M |
| Float | 62.81M |
| Short Ratio | 1.84 |
| % Held by Insiders | 19.20% |
| % Held by Institutions | 32.17% |
| Shares Short | 796.23K |
| Short % of Float | 1.27% |
| Short % of Shares Outstanding | 0.97% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1336.94% |
| Gross Margin | 271.20% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -20.48% |
| Return on Equity (ttm) | -75.043% |
Income Statement
| Revenue (ttm) | 4.27M USD |
| Revenue Per Share (ttm) | 0.06 USD |
| Quarterly Revenue Growth (yoy) | -43.39% |
| Gross Profit (ttm) | 4.8M USD |
| EBITDA | -56298000 USD |
| Net Income Avi to Common (ttm) | -59935000 USD |
| Diluted EPS (ttm) | -0.92 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 138.99M USD |
| Total Cash Per Share (mrq) | 1.72 USD |
| Total Debt (mrq) | 21.42M USD |
| Total Debt/Equity (mrq) | 36.49 USD |
| Current Ratio (mrq) | 8.252 |
| Book Value Per Share (mrq) | 0.729 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -3316000 USD |
| Levered Free Cash Flow (ttm) | -34701752 USD |
Profile of ProQR Therapeutics
| Country | United States |
| State | N/A |
| City | Leiden |
| Address | Zernikedreef 9 |
| ZIP | 2333 CK |
| Phone | 31 88 166 7000 |
| Website | https://www.proqr.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 130 |
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; AX-9115 for rare metabolic condition; and AX-2402 for rare neurodegenerative conditions, as well as other targets in its discovery pipeline. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Q&A For ProQR Therapeutics Stock
What is a current PRQR stock price?
ProQR Therapeutics PRQR stock price today per share is 2.09 USD.
How to purchase ProQR Therapeutics stock?
You can buy PRQR shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ProQR Therapeutics?
The stock symbol or ticker of ProQR Therapeutics is PRQR.
Which industry does the ProQR Therapeutics company belong to?
The ProQR Therapeutics industry is Biotechnology.
How many shares does ProQR Therapeutics have in circulation?
The max supply of ProQR Therapeutics shares is 105.35M.
What is ProQR Therapeutics Price to Earnings Ratio (PE Ratio)?
ProQR Therapeutics PE Ratio is now.
What was ProQR Therapeutics earnings per share over the trailing 12 months (TTM)?
ProQR Therapeutics EPS is -0.48 USD over the trailing 12 months.
Which sector does the ProQR Therapeutics company belong to?
The ProQR Therapeutics sector is Healthcare.
ProQR Therapeutics PRQR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23578.13 USD — |
+0.31
|
7.36B USD — | 23506 USD — | 23680.03 USD — | — - | 7.36B USD — |
| US Tech Composite Total Return XCMP | 28982.4 USD — |
+0.32
|
— — | 28893.75 USD — | 29107.65 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech Global Market Composite NQGM | 2284.72 USD — |
-0.03
|
— — | 2279.63 USD — | 2295 USD — | — - | — — |
| US Tech Biotechnology NBI | 5738.87 USD — |
-0.45
|
— — | 5719.89 USD — | 5783.12 USD — | — - | — — |
| US Tech Health Care IXHC | 1198.62 USD — |
-0.27
|
— — | 1196.61 USD — | 1205.97 USD — | — - | — — |
- {{ link.label }} {{link}}